In studies evaluating the efficacy of nivolumab in recurrent brain tumors against bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, the outcome of patients treated with cortisone in addition to nivolumab was found to be worse than in patients treated with nivolumab without cortisone (85). This evidence concerns the gene VEGFA and brain neoplasm.